VivoSim Labs Inc
organovo.comVivoSim Labs Inc (VIVS) is a pharmaceutical and biotechnology services company that provides drug and drug candidate testing using three-dimensional human tissue models of liver and intestine. Revenue is generated through service contracts with pharmaceutical partners, with license agreements structured to include upfront fees and sales-based royalties on products incorporating the company's intellectual property, per the 10-K filed 2025-06-05. The company offers liver and intestinal toxicology insights via new approach methodologies (NAM) models, as well as bespoke investigational toxicology and mechanism of drug action services. Formerly known as Organovo Holdings Inc, VivoSim pivoted in March 2025 away from clinical-stage drug development of FXR314 in inflammatory bowel disease to its current services focus. Executive Chairman Keith Murphy and key personnel lead the organization. The company raised net proceeds of approximately $4.5 million from a May 2024 public offering, and the 10-K filing discloses ongoing reliance on external financing, with insufficient funds identified as a material risk to operations.
Products & Services
Three-dimensional human liver and intestine tissue models for drug toxicology testing; new approach methodologies (NAM) models for liver and intestinal toxicology insights; bespoke investigational toxicology services; mechanism of drug action elucidation services. Previously developed FXR314, a clinical-stage compound for inflammatory bowel disease including ulcerative colitis and Crohn's disease, development of which was discontinued as of March 2025 per 10-K filed 2025-06-05.
Revenue Model
Service contracts with pharmaceutical and biotechnology partners for 3D tissue model testing, plus license agreements that include non-refundable upfront fees (fixed) and sales-based royalties (variable) tied to partner product sales incorporating VivoSim's licensed IP, per 10-K filed 2025-06-05.
Customers & Markets
Pharmaceutical and biotechnology companies seeking non-animal drug testing alternatives. End market demand tied to FDA regulatory shifts toward NAM methods, per FDA announcement on April 10, 2025 referenced in 10-K filed 2025-06-05. No specific customer names or concentration data disclosed in the filing excerpts.
Geographic Exposure
U.S.-based operations; EU GDPR compliance obligations noted, indicating some international data processing exposure. No specific revenue by geography disclosed in the filing excerpts.
Financial Snapshot
Loading...
